Revolution Medicines, Inc. reiterated earnings guidance for the full year 2024. The company is reiterating its projected full year 2024 GAAP net loss to be between $480 million and $520 million, which includes estimated non-cash stock-based compensation expense of between $70 million and $80 million.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
39.81 USD | +0.10% | +1.77% | +38.35% |
May. 09 | Wedbush Raises Price Target on Revolution Medicines to $46 From $42, Maintains Outperform Rating | MT |
May. 08 | Revolution Medicines Q1 Net Loss Narrows | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+38.35% | 6.56B | |
+62.70% | 62.59B | |
-1.21% | 41.18B | |
+44.76% | 40.29B | |
-8.29% | 27.9B | |
+13.04% | 26.21B | |
-21.51% | 19.09B | |
+5.43% | 13.08B | |
+25.09% | 12.26B | |
+28.39% | 12.05B |
- Stock Market
- Equities
- RVMD Stock
- News Revolution Medicines, Inc.
- Revolution Medicines, Inc. Reiterates Earnings Guidance for the Full Year 2024